Venous Thrombo-Embolism in Hospitalized SARS-CoV-2 Patients Treated with Three Different Anticoagulation Protocols: Prospective Observational Study
The purpose of this study is to assess thrombotic risk in CoViD-19/pneumonia patients with acute respiratory failure and to compare populations treated with three different antithrombotic prophylaxis protocols. The primary outcome is to analyze the prevalence of thrombotic events in hospitalized pat...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Biology |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-7737/9/10/310 |
id |
doaj-a1419db394c54231b7f4e48fa4215743 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yaroslava Longhitano Fabrizio Racca Christian Zanza Marina Muncinelli Alberto Guagliano Elisa Peretti Anna Chiara Minerba Marta Mari Riccardo Boverio Mario Salio Guido Chichino Francesco Franceschi Andrea Piccioni Ludovico Abenavoli Mauro Salvini Marco Artico |
spellingShingle |
Yaroslava Longhitano Fabrizio Racca Christian Zanza Marina Muncinelli Alberto Guagliano Elisa Peretti Anna Chiara Minerba Marta Mari Riccardo Boverio Mario Salio Guido Chichino Francesco Franceschi Andrea Piccioni Ludovico Abenavoli Mauro Salvini Marco Artico Venous Thrombo-Embolism in Hospitalized SARS-CoV-2 Patients Treated with Three Different Anticoagulation Protocols: Prospective Observational Study Biology Covid-19 acute respiratory failure deep vein thrombosis coagulopathy venous thromboembolism thromboprophylaxis |
author_facet |
Yaroslava Longhitano Fabrizio Racca Christian Zanza Marina Muncinelli Alberto Guagliano Elisa Peretti Anna Chiara Minerba Marta Mari Riccardo Boverio Mario Salio Guido Chichino Francesco Franceschi Andrea Piccioni Ludovico Abenavoli Mauro Salvini Marco Artico |
author_sort |
Yaroslava Longhitano |
title |
Venous Thrombo-Embolism in Hospitalized SARS-CoV-2 Patients Treated with Three Different Anticoagulation Protocols: Prospective Observational Study |
title_short |
Venous Thrombo-Embolism in Hospitalized SARS-CoV-2 Patients Treated with Three Different Anticoagulation Protocols: Prospective Observational Study |
title_full |
Venous Thrombo-Embolism in Hospitalized SARS-CoV-2 Patients Treated with Three Different Anticoagulation Protocols: Prospective Observational Study |
title_fullStr |
Venous Thrombo-Embolism in Hospitalized SARS-CoV-2 Patients Treated with Three Different Anticoagulation Protocols: Prospective Observational Study |
title_full_unstemmed |
Venous Thrombo-Embolism in Hospitalized SARS-CoV-2 Patients Treated with Three Different Anticoagulation Protocols: Prospective Observational Study |
title_sort |
venous thrombo-embolism in hospitalized sars-cov-2 patients treated with three different anticoagulation protocols: prospective observational study |
publisher |
MDPI AG |
series |
Biology |
issn |
2079-7737 |
publishDate |
2020-09-01 |
description |
The purpose of this study is to assess thrombotic risk in CoViD-19/pneumonia patients with acute respiratory failure and to compare populations treated with three different antithrombotic prophylaxis protocols. The primary outcome is to analyze the prevalence of thrombotic events in hospitalized patients, while the secondary outcome is to analyze the correlation between different anticoagulation targets with thrombotic events. All patients referred to our hospital for acute respiratory failure due to COVID-19 pneumonia between 18 and 31 May 2020 were included. Seventy-four patients were enrolled (44 men and 30 women, average age 68.6). Diagnosis of venous thromboembolism was made in 21 cases (28.4%) and thrombotic events were associated with positive pressure ventilation support (<i>p</i> = 0.024) and hospitalization in ICU (<i>p</i> < 0.0001). These patients presented higher levels of D-dimer (<i>p</i> < 0.0001) and their hospital length of stay was >16 days longer. Forty-seven out of 74 patients (63.5%) received intermediate or therapeutic dose of anticoagulation, while twenty-seven patients (34.5%) received standard antithrombotic prophylaxis. The analysis showed that an intermediate or therapeutic dose of anticoagulation did not decrease the prevalence of thrombotic events. On the other hand, six patients reported severe hemorrhagic complications. Despite intermediate or therapeutic-dose of anticoagulation, a high number of patients with acute respiratory failure secondary to COVID-19 developed thrombotic complications. |
topic |
Covid-19 acute respiratory failure deep vein thrombosis coagulopathy venous thromboembolism thromboprophylaxis |
url |
https://www.mdpi.com/2079-7737/9/10/310 |
work_keys_str_mv |
AT yaroslavalonghitano venousthromboembolisminhospitalizedsarscov2patientstreatedwiththreedifferentanticoagulationprotocolsprospectiveobservationalstudy AT fabrizioracca venousthromboembolisminhospitalizedsarscov2patientstreatedwiththreedifferentanticoagulationprotocolsprospectiveobservationalstudy AT christianzanza venousthromboembolisminhospitalizedsarscov2patientstreatedwiththreedifferentanticoagulationprotocolsprospectiveobservationalstudy AT marinamuncinelli venousthromboembolisminhospitalizedsarscov2patientstreatedwiththreedifferentanticoagulationprotocolsprospectiveobservationalstudy AT albertoguagliano venousthromboembolisminhospitalizedsarscov2patientstreatedwiththreedifferentanticoagulationprotocolsprospectiveobservationalstudy AT elisaperetti venousthromboembolisminhospitalizedsarscov2patientstreatedwiththreedifferentanticoagulationprotocolsprospectiveobservationalstudy AT annachiaraminerba venousthromboembolisminhospitalizedsarscov2patientstreatedwiththreedifferentanticoagulationprotocolsprospectiveobservationalstudy AT martamari venousthromboembolisminhospitalizedsarscov2patientstreatedwiththreedifferentanticoagulationprotocolsprospectiveobservationalstudy AT riccardoboverio venousthromboembolisminhospitalizedsarscov2patientstreatedwiththreedifferentanticoagulationprotocolsprospectiveobservationalstudy AT mariosalio venousthromboembolisminhospitalizedsarscov2patientstreatedwiththreedifferentanticoagulationprotocolsprospectiveobservationalstudy AT guidochichino venousthromboembolisminhospitalizedsarscov2patientstreatedwiththreedifferentanticoagulationprotocolsprospectiveobservationalstudy AT francescofranceschi venousthromboembolisminhospitalizedsarscov2patientstreatedwiththreedifferentanticoagulationprotocolsprospectiveobservationalstudy AT andreapiccioni venousthromboembolisminhospitalizedsarscov2patientstreatedwiththreedifferentanticoagulationprotocolsprospectiveobservationalstudy AT ludovicoabenavoli venousthromboembolisminhospitalizedsarscov2patientstreatedwiththreedifferentanticoagulationprotocolsprospectiveobservationalstudy AT maurosalvini venousthromboembolisminhospitalizedsarscov2patientstreatedwiththreedifferentanticoagulationprotocolsprospectiveobservationalstudy AT marcoartico venousthromboembolisminhospitalizedsarscov2patientstreatedwiththreedifferentanticoagulationprotocolsprospectiveobservationalstudy |
_version_ |
1724644936025899008 |
spelling |
doaj-a1419db394c54231b7f4e48fa42157432020-11-25T03:14:02ZengMDPI AGBiology2079-77372020-09-01931031010.3390/biology9100310Venous Thrombo-Embolism in Hospitalized SARS-CoV-2 Patients Treated with Three Different Anticoagulation Protocols: Prospective Observational StudyYaroslava Longhitano0Fabrizio Racca1Christian Zanza2Marina Muncinelli3Alberto Guagliano4Elisa Peretti5Anna Chiara Minerba6Marta Mari7Riccardo Boverio8Mario Salio9Guido Chichino10Francesco Franceschi11Andrea Piccioni12Ludovico Abenavoli13Mauro Salvini14Marco Artico15Department of Anesthesiology and Critical Care Medicine, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, ItalyDepartment of Anesthesiology and Critical Care Medicine, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, ItalyDepartment of Anesthesiology and Critical Care Medicine, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, ItalyDepartment of Vascular Surgery, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, ItalyDepartment of Vascular Surgery, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, ItalyDepartment of Vascular Surgery, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, ItalyDepartment of Vascular Surgery, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, ItalyDepartment of Vascular Surgery, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, ItalyDepartment of Emergency Medicine, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, ItalyDepartment of Internal Medicine, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, ItalyDepartment of Internal Medicine, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, ItalyDepartment of Anesthesiology and Emergency Sciences, Policlinico Gemelli/IRCCS-Catholic University of Sacred Heart, 00168 Rome, ItalyDepartment of Anesthesiology and Emergency Sciences, Policlinico Gemelli/IRCCS-Catholic University of Sacred Heart, 00168 Rome, ItalyDepartment of Health Sciences, Magnae Grecia University of Catanzaro, 88100 Catanzaro, ItalyDepartment of Vascular Surgery, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, ItalyDepartment of Sensory Organs, Sapienza University of Rome Policlinico Umberto I, 00155 Rome, ItalyThe purpose of this study is to assess thrombotic risk in CoViD-19/pneumonia patients with acute respiratory failure and to compare populations treated with three different antithrombotic prophylaxis protocols. The primary outcome is to analyze the prevalence of thrombotic events in hospitalized patients, while the secondary outcome is to analyze the correlation between different anticoagulation targets with thrombotic events. All patients referred to our hospital for acute respiratory failure due to COVID-19 pneumonia between 18 and 31 May 2020 were included. Seventy-four patients were enrolled (44 men and 30 women, average age 68.6). Diagnosis of venous thromboembolism was made in 21 cases (28.4%) and thrombotic events were associated with positive pressure ventilation support (<i>p</i> = 0.024) and hospitalization in ICU (<i>p</i> < 0.0001). These patients presented higher levels of D-dimer (<i>p</i> < 0.0001) and their hospital length of stay was >16 days longer. Forty-seven out of 74 patients (63.5%) received intermediate or therapeutic dose of anticoagulation, while twenty-seven patients (34.5%) received standard antithrombotic prophylaxis. The analysis showed that an intermediate or therapeutic dose of anticoagulation did not decrease the prevalence of thrombotic events. On the other hand, six patients reported severe hemorrhagic complications. Despite intermediate or therapeutic-dose of anticoagulation, a high number of patients with acute respiratory failure secondary to COVID-19 developed thrombotic complications.https://www.mdpi.com/2079-7737/9/10/310Covid-19acute respiratory failuredeep vein thrombosiscoagulopathyvenous thromboembolismthromboprophylaxis |